Phase Forward Delivers Enhanced Integration Capabilities as Part of Ongoing Adapter Strategy
InForm Adapter, Available Immediately, Strengthens Integration with Existing Customer Data and Systems.
WALTHAM, Mass.-June 12, 2006-Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the new InForm™ Adapter module, providing customers with enhanced integration capabilities for the InForm Integrated Trial Management (ITM) electronic data capture (EDC) solution. With the InForm Adapter module, InForm ITM users can leverage a set of Web services-based interfaces to access data and event information stored in the InForm database. The result is a broader set of integrated and extensible clinical workflow solutions that better leverage InForm ITM users' existing proprietary systems and packaged applications.
The announcement reflects the company's strategy to deliver greater integration and extensibility for Phase Forward customers through adapters. Providing adapters that leverage Web services standards creates an architecture that allows more integration points to be added more quickly in the future.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
VYNE Ends Phase IIb Vitiligo Trial of Repibresib After Missing Primary Endpoint
July 30th 2025VYNE Therapeutics will terminate its Phase IIb trial of topical Repibresib gel in nonsegmental vitiligo after failing to meet F-VASI50 and F-VASI75 endpoints at week 24, despite nominally significant improvements in other secondary and exploratory measures.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
J&J Submits sBLA to FDA for Tremfya Label Expansion Based on PsA Joint Damage Inhibition Data
July 29th 2025The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.
